Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

@article{McGuire2000TopotecanHS,
  title={Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.},
  author={William Patrick McGuire and John A. Blessing and Michael A. Bookman and Samuel S. Lentz and Charles J. Dunton},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2000},
  volume={18 5},
  pages={1062-7}
}
PURPOSE Topotecan is known to be active in recurrent ovarian cancer, but most prior studies have focused on platinum-resistant or refractory populations. This study was undertaken to define the response rate and progression-free interval in platinum-sensitive patients. PATIENTS AND METHODS Patients with recurrent ovarian cancer after one or two prior chemotherapy regimens and in whom the interval between prior platinum therapy and the initiation of protocol therapy was greater than 6 months… CONTINUE READING